This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BDSI BioDelivery Sciences International (BDSI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioDelivery Sciences International Stock (NASDAQ:BDSI) Get BDSI alerts:Sign Up Key Stats Today's Range$5.59▼$5.6050-Day Range$5.54▼$5.6052-Week Range$2.50▼$5.62Volume2.09 million shsAverage Volume3.34 million shsMarket Capitalization$577.05 millionP/E Ratio6.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc. Read More Receive BDSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDSI Stock News HeadlinesVaxart Appoints W. Mark Watson as Lead Independent Director and Encourages Stockholder Participation in Upcoming Vote on Reverse Stock SplitSeptember 17, 2025 | quiverquant.comQFlorida International UniversitySeptember 14, 2023 | usnews.com1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.October 10 at 2:00 AM | Base Camp Trading (Ad)International High School for Health SciencesMay 6, 2023 | usnews.comInternational climate change bodies win humanity awardOctober 15, 2022 | omaha.comOPerilous Reversal Watch: BioDelivery Sciences International (BDSI)September 16, 2022 | thestreet.comScienceSeptember 13, 2022 | npr.orgNCollegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | seekingalpha.comSee More Headlines BDSI Stock Analysis - Frequently Asked Questions How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company earned $41.09 million during the quarter, compared to the consensus estimate of $42.05 million. BioDelivery Sciences International had a net margin of 50.90% and a trailing twelve-month return on equity of 21.25%. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/02/2021Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDSI CIK1103021 Webwww.bdsi.com Phone(919) 582-9050Fax919-582-9051Employees200Year Founded1997Profitability EPS (Trailing Twelve Months)$0.83 Trailing P/E Ratio6.74 Forward P/E Ratio14.71 P/E GrowthN/ANet Income$84.86 million Net Margins50.90% Pretax Margin17.77% Return on Equity21.25% Return on Assets10.56% Debt Debt-to-Equity Ratio0.29 Current Ratio2.45 Quick Ratio2.17 Sales & Book Value Annual Sales$166.70 million Price / Sales3.46 Cash Flow$0.36 per share Price / Cash Flow15.42 Book Value$1.90 per share Price / Book2.94Miscellaneous Outstanding Shares103,229,000Free Float92,927,000Market Cap$577.05 million OptionableOptionable Beta0.56 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BDSI) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioDelivery Sciences International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
